Comparative Pharmacology
Head-to-head clinical analysis: DUEXIS versus NAPROXEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUEXIS versus NAPROXEN.
DUEXIS vs NAPROXEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
250-500 mg orally twice daily; maximum 1.5 g/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateNaproxen + Gatifloxacin
"Naproxen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNaproxen + Rosoxacin
"Naproxen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNaproxen + Levofloxacin
"Naproxen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNaproxen + Trovafloxacin
"Naproxen may increase the neuroexcitatory activities of Trovafloxacin."
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life 12-17 hours (mean 14 hours); permits twice-daily dosing. Half-life prolonged in elderly and hepatic impairment.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Primarily renal (95% as unchanged naproxen and 6-O-desmethylnaproxen); <5% fecal via biliary excretion.
Category C
Category D/X
NSAID/H2 Antagonist Combination
NSAID